Drug Prohibition And Public HealthPublic Health Reports, Journal Of The US Public Health Service, Jan-Feb, 1999Room 1855, JFK Federal Building, Boston, MA 02203
"We are making a difference. Drug use is down 50% over the last decade." - President William J. Clinton, Preface to The National Drug Control Strategy, 1998 [1] "When assessing evidence, it is helpful to see a full data matrix, all observations for all variables, those private numbers from which the public displays are constructed. No telling what will turn up." - Edward R. Tufte [2]
S Y N O P S I SFOR THE PAST 25 YEARS, the US has pursued a drug policy based on prohibition and the vigorous application of criminal sanctions for the use and sale of illicit drugs. The relationship of a prohibition-based drug policy to prevalence patterns and health consequences of drug use has never been fully evaluated.To explore that relationship, the author examines national data on the application of criminal penalties for illegal drugs and associated trends in their patterns of use and adverse health out-comes for 1972-997.
Over this 25-year period, the rate at which criminal penalties are imposed
for drug offenses has climbed steadily, reaching 1.5 million arrests for
drug offenses in 1996, with a tenfold increase in imprisonment for drug
charges since 1979. Today, drug enforcement activities constitute 67% of
the $16 billion Federal drug budget and more than $20 billion per year in
state and local enforcement expenditures, compared with $7.6 billion for
treatment, prevention, and research. ADVERSE OUTCOMESDAWN was established in the mid-1970s by the Federal government to monitor two important outcomes of drug use--drug-related hospital ER admissions and deaths in which drugs are implicated. Surprisingly, these data show a distinctly different time trend from the data on the prevalence of drug use in the same time period (Figures 5 and 6). Both drug-related ER visits and deaths climbed steadily after 1979, the peak year for all drug use, rose most sharply in the mid-1980s just as the prevalence of use was declining most rapidly, and continued to rise through the 1990s, despite low and stable drug prevalence among adults. Drug- related ER visits rose by 60% from 1978 to 1994 (from 323,100 annually to 518,500) while overall ER visits increased by only 26%. [22] These increases are most strongly associated with the use of cocaine and heroin (Figure 8), which together account for fewer than 4% of all illegal drug use but are mentioned in more than 40% of all drug-related ER visits and more than 90% of deaths due to overdoses. And while there are a growing number of overdose deaths seen among the new, younger users of heroin, [1] the age-adjusted death rates show increases in every age group for the period 1985-1995,22 with the highest rates in the 35-44 age group (an older cohort of established users). [23] Overall, drug-related deaths more than quadrupled from 1976 to 1995--from 2136 to 9097 annually.(See Figure 9.) It would appear that drug use is becoming more dangerous. Even as the numbers of drug users have gone down, the per-user rates of ER visits and fatalities have been much higher since the mid-1980s. If we measure the success of our drug policy in terms of adverse public health outcomes instead of prevalence of drug use, it is clear that we are doing worse, not better. But if the time trends in drug-related morbidity and mortality do not correspond to trends in the overall prevalence of adult drug use, as we would expect them to, what accounts for the sharp climb in both as prevalence declined? And to what extent is this increase a reflection or result of our drug policy? To answer these questions it is necessary to disaggregate the data. DRUG POLICY IN BLACK AND WHITE Disaggregating the data on adverse outcomes and drug enforcement by "race" suggests that the greater the intensity of criminal penalties, the greater the public health danger of drugs. The enforcement of drug laws is not applied equally to all groups: despite comparable rates of drug use, African Americans are disproportionately represented among imprisoned drug offenders. Figure 10 shows white, black, and Hispanic drug law violators as a proportion of all state prison inmates for 1986 and 1991. Today, state prison incarceration rates for African Americans for drug law violations are almost 20 times those of whites and more than double those of Hispanics. [14] From 1990 to 1994, incarceration for drug offenses accounted for 60% of the increase in the black population in state prisons and 91% of the increase in Federal prisons. [14] This trend corresponds to the higher proportion of African Americans incarcerated for all reasons: 6296 per 100,000 adults in 1995, compared with 919 per 100,000 for whites--a ratio of 7.5 to 1. [14] By 1995, 35% of all African American males ages 25-34 were under the control of the criminal justice system--behind bars, on probation, or on parole. [39] Drug enforcement (arrests, incarcerations, probation, parole) may itself be considered another adverse out-come of drug use--a measure of social morbidity with enormous negative consequences for those caught up in the criminal justice system. The damages that a prison record does to a young person's self-esteem and social and economic prospects are well known. In addition, a recent study reveals that in 1998, 3.9 million convicted felons (which includes all drug offenders), were disenfranchised as citizens and lost the right to vote. [40] Reflecting the disproportionately high rates of prosecution for drug offenses, disenfranchisement of African Americans occurs at three to four times the rate of whites. In states with the most restrictive voting laws, as many as 40% of African American men are likely to be permanently disenfranchised, according to the study's authors. [40] I would suggest, however, that drug enforcement can also be viewed as an independent variable--a causal factor responsible for worsening many of the social and public health problems that we normally attribute to drug use per se. Effects Of Differential Enforcement. Prohibition criminalizes all drug users, buyers and sellers equally. For those who are drug-dependent or addicted and cannot gain access to effective treatment, these laws dictate a life of crime and of degradation, deceit, and (for the poor) prostitution and drug trafficking to obtain the money needed to shop in a violent and expensive marketplace. Further, the drug user is continually exposed to risks to health and life--to infectious diseases through the re-use of injecting equipment (also criminalized and still prosecuted under drug paraphenalia laws) and to the unpredictable effects of illicit substances of unknown purity or potency. The powerful stigma of addiction relentlessly pushes the addict to the margins of society, away from family and social supports, medical attention, and employment--all factors that mitigate the dangers of drug use and promote recovery. [41] Although these pervasive influences of prohibition affect all users of prohibited drugs, the data show that the most negative health consequences of drug use are not evenly distributed--they fall most heavily on those who experience the highest rates of drug enforcement, African Americans. When the data are adjusted for the correct population denominators, they reveal a huge discrepancy in rates of adverse outcomes. While we see an overall rise in drug-related ER admissions for the total population throughout a long period of declining drug use (especially declines in the use of cocaine), these rates are very different across "racial" subgroups. African Americans fare dramatically worse than whites; in 1996, African Americans had 7.5 times the white rate of heroin-related emergency department visits and 11.5 times the white rate of cocaine-related visits (Table 2). In 1996, African Americans, who represent only 12% of the US adult population [42] and a similar percentage of drug users, accounted for 57% of ER drug admissions while whites (75% of the population 26 and a proportionate number of drug users) accounted for 31%. [12] A similar pattern is seen in the racially disaggregated data on overdose deaths in this period. African Americans have 3.5 times the rate of drug fatalities of whites,36 and while the overall trend is an increase for all groups, from 1980 to 1993 there was a 326% increase in drug abuse deaths for blacks but a 129% increase for whites and others (Figure 11). CONCLUSION: DRUG PROHIBITION VS PUBLIC HEALTH Large disparities in drug-related morbidity and mortality appear to be a powerful consequence of prohibition drug policies and their unequal application in our society. (See Table 3.) But they also point to a set of larger problems, evident in the historic relationship of US drug policies to public health. In the United States we have a long history of strong public sentiment about the use of all intoxicating substances--we alone in the Western world altered our national Constitution to ban alcohol for 14 years. Today's drug policies may be understood as the expression of an (almost) innocent wish to make dangerous drugs disappear by legislating their prohibition. A plausible case can be made that as drug use rose in the 1960s and 1970s, extending more widely and more openly into middle-class America, increasingly severe criminal penalties for the use of prohibited drugs and more rigorous enforcement was a predictable response. While the avowed motive of this policy, restraining the damages that can be caused by drugs, was (and is) a legitimate social goal, the cure has only worsened the disease. Drug laws and their massive, cruel imposition on millions of young men and women--not simply the use of drugs--have stigmatized and estranged our most disadvantaged minorities, creating a "new American Gulag" [18] with its own archipelago of prisons, jails, courts, probation, parole, and, most recently, compulsory treatment as an alternative to incarceration, blurring the boundary between treatment and punishment. As we build prisons instead of schools, the images of young black men being arrested and imprisoned for drug offenses continue to fill the news media. While all the data suggest little systematic difference in the prevalence of drug use by "race" or ethnicity, these images foster the belief that nonwhite Americans use drugs more than other Americans--an assumption that goes largely unexamined by a public systematically frightened about our children's almost inevitable exposure to drugs.43 At the same time, our prejudicial enforcement of drug laws and the wholesale criminalization of a large cohort of young inner-city residents serves to sustain and reinforce this stereotype while fostering social, economic, and political disenfranchisement [44] and increasing the health and life risk associated with use of drugs. Drugs can certainly cause harm, but our selective application of punitive drug prohibition laws are at least as dangerous. These laws have spawned a lethal biosocial ecology in which the poorest nations and communities are ravaged by uncontrolled criminal drug markets, [45] emerging infectious diseases,46 and the widespread corruption of civil society. [47] Drugs are cheaper, more powerful, and more available today then at any time in the past 25 years. This new and complex political reality cries out for effective policies based on sound science, public health priorities and human rights. [48-50] Yet, after nearly a century of a bankrupt approach to drug control, we see no end in sight. In June 1998, delegates from all over the world heard Pino Arlacchi, Executive Director of the UN Office for Drug Control and Crime Prevention, address the General Assembly's Special Session on International Drug Control with calls "to start the real war against drugs and convince nations and people that there could be a drug-free world." [51] Effective and publicly acceptable alternatives to a prohibition- based policy are now available to us in the form of harm reduction approaches (including needle exchange programs, low threshold treatment, and improved access to housing and health care for drug users). Harm reduction is already national policy in a score of countries throughout the world. [52] But in the US the very use of the term harm reduction is still banned from the Federal policy lexicon and denied funding because it is seen as "condoning drug use." Its proponents are vilified as supporters of drug legalization, [53,54] and critics within the government are cowed into silence (or anxiously whispered support at AIDS conferences). And there can be severe penalties for open dissent--as we saw in the case of Surgeon General Joycelyn Elders. These are not-so-early warning signs of a great American failure--not only in drug policy but in our native capacity for creative, compassionate, and above all open discourse about issues vital to our well-being. It is time that we move beyond this drug fundamentalism and abandon our unhappy history of prohibition for more humane and pragmatic policies that protect public health and support our democratic values. The author thanks Jennifer McNeely for assistance with this article. REFERENCES 1. Clinton WJ. The President's message. In: Office of National Drug Control Policy (US). The National Drug Control Strategy, 1998: a ten year plan. Washington: ONDCP; 1998. 2. Tufte ER. Visual explanation: images and quantities, evidence and narrative. Cheshire (CT): Graphic Press; 1997. 3. Drucker E. Harm reduction: a public health strategy. Current Issues Public Health 1995;1:64-70. 4. Substance Abuse and Mental Health Services Administration (US). National Household Survey on Drug Abuse. Series H-5: main findings. Washington: SAMSHA; 1996. 5. Grund JPC, Stern LS, Kaplan CD, Adriaans NFP, Drucker E. Drug use context and HIV consequences: the effects of drug policy on everyday drug use in Rotterdam and the Bronx. Br J Addictions 1992;87:41-52. 6. NIH Consensus Development Conference on Methadone, November 17-19, 1997. Effective Medical Treatment of Opiate Addiction 1997; 15(6):1-38 [cited 1998 Nov 16]. Available from: URL: http://www.opd.od.nih.gov/consensus/cons/108/108_statement.htm 7. Institute of Medicine. Effectiveness of drug treatment. Vol. 1. Washing-ton: National Academy Press; 1995. 8. Swarms J. Mayor steps up his criticism of Methadone: accuses drug pro-grams of enslaving ex-addicts. New York Times 1998 Aug 16. Sect. A:33. 9. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997;349:604-8. 10. McCaffery BR. A strategy for confronting the nation's drug problem. San Diego Union Tribune 1998 Aug 2. 11. Office of National Drug Control Policy (US). National Drug Control Strategy budget summary 1997: FY 1998. Washington: ONCDP; 1998. 12. Department of Justice, Office of Justice Programs (US). Bureau of Justice Statistics sourcebook of criminal justice statistics: 1996. Washington: DOJ; 1997. 13. Mark T, McKusick D, King E, Harwood H, Genuardi J. Health care spending: national expenditures for mental health, alcohol and other drug abuse treatment, 1996: prepublication release. Washington: Substance Abuse and Mental Health Services Administration (US); 1998 Sep. 14. Department of Justice, Bureau of Justice Statistics (US). Trends in US correctional populations, 1995. Rockville (MD): Bureau of Justice Statistics; 1996. 15. Department of Justice, Bureau of Justice Statistics (US). Sourcebook 1992: correctional populations in the US. Rockville (MD): Bureau of Justice Statistics; 1993. 16. Department of Justice, Bureau of Justice Statistics (US). Drugs, crime, and the justice system : a national report. Rockville (MD): Bureau of Justice Statistics; 1992. 17. Lindesmith Center. Drug prohibition and the US prison system. New York: The Center; 1998. 18. Christie N. Crime control as industry. London (UK): Routledge; 1993. 19. National Institute on Drug Abuse (US). National survey results from Monitoring the Future study, 1975–1995. Rockville (MD): National Institutes of Health; 1996. Pub. No. 96-4139. 20. Substance Abuse and Mental Health Services Administration (US). National Household Survey on Drug Abuse population estimates, 1997. Series H-7. Rockville (MD): Department of Health and Human Services; 1998. 21. Substance Abuse and Mental Health Services Administration (US). Preliminary results from the National Household Survey of Drug Abuse, 1997. Series H-6. Rockville (MD): National Clearinghouse for Alcohol and Drug Information; 1998. 22. National Institute on Drug Abuse (US). Topical data from the Drug Abuse Warning Network (DAWN), 1976–1985, and mid-year preliminary estimates, 1996: trends in drug abuse related hospital emergency room episodes and medical examiner cases. Series H. No. 3. Rockville (MD): National Institutes of Health; 1996. 23. Fingerhut LA, Cox CS. Poisoning mortality, 1985-1995. Public Health Rep 1998;113:218-33. 24. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1981. Series I. No. 1. Rockville (MD): Department of Health and Human Services; 1982. 25. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1982. Series I. No. 2. Rockville (MD): Department of Health and Human Services; 1983. 26. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1983. Series I. No. 3. Rockville (MD): Department of Health and Human Services; 1984. 27. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1984. Series I. No. 4. Rockville (MD): Department of Health and Human Services; 1985. 28. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1985. Series I. No. 5. Rockville (MD): Department of Health and Human Services; 1986. 29. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1986. Series I. No. 6. Rockville (MD): Department of Health and Human Services; 1987. 30. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1987. Series I. No. 7. Rockville (MD): Department of Health and Human Services; 1988. 31. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1988. Series I. No. 8. Rockville (MD): Department of Health and Human Services; 1989. 32. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1989. Series I. No. 9. Rockville (MD): Department of Health and Human Services; 1990. 33. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1990. Series I. No. 10. Rockville (MD): Department of Health and Human Services; 1991. 34. National Institute on Drug Abuse (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1991. Series I. No. 11. Rockville (MD): Department of Health and Human Services; 1992. 35. Substance Abuse and Mental Health Services Administration (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1992. Series I. No. 12-B. Rockville (MD): Department of Health and Human Services; 1994. 36. Substance Abuse and Mental Health Services Administration (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1993. Series I. No. 13-B. Rockville (MD): Department of Health and Human Services; 1995. 37. Substance Abuse and Mental Health Services Administration (US). Data from the Drug Abuse Warning Network (DAWN): annual medical examiner data, 1994. Series I. No. 14-B. Rockville (MD): Department of Health and Human Services; 1996. 38. Substance Abuse and Mental Health Services Administration (US). Drug Abuse Warning Network annual medical examiner data, 1995. Series D-1. Rockville (MD): Department of Health and Human Services; 1997. 39. Mauer M, Huling T. Young black Americans and the criminal justice system. Washington: The Sentencing Project; 1995. 40. Fellner J, Mauer M. Losing the vote: impact of disenfranchisement laws in the US. Washington: The Sentencing Project and Human Rights Watch; 1998 41. Waldorf D, Reinerman C, Murphy S. Cocaine changes. Philadelphia: Temple University Press; 1991. 42. Department of Commerce, Bureau of the Census (US). Population estimates from Statistical Abstract of the US: 1994. Washington: The Bureau; 1995. 43. Partnership for a Drug Free America [cited 1998 Dec 5]. Available from: URL: http://www.drugfreeamerica.org/parents/html 44. Tonry M. Malign neglect: race, crime, and punishment in America. New York: Oxford University Press; 1995. 45. Garrett L. The coming plague: newly emerging infections in a world out of control. New York: Farrar, Straus and Giroux; 1994 46. Stares P. Global habit : the drug problem in a borderless world. Washington: The Brookings Institution; 1996. 47. Andreas P. Profits, poverty, and inequality: the logic of drug corruption. NACLA Report on the Americas 1993; 27(3):22-8. 48. Nadelmann E. Commonsense drug policy. Foreign Affairs 1998;77:111-26. {MAP URLs: http://www.mapinc.org/drugnews/v98/n032/a04.html http://www.mapinc.org/drugnews/v98/n032/a03.html } 49. Drucker E, Lurie P, Alcabes P, Wodak A. Measuring harm reduction: the effects of needle and syringe exchange programs and Methadone maintenance on the ecology of HIV. AIDS 98 1998;12 Suppl A:S217-S230. 50. Mann J, Tarantola D, editors. AIDS in the world II. New York: Oxford University Press; 1996. 51. Wren C. UN Special session on drugs meets in New York. New York Times 1998 Jun 7. Sect. A:7. 52. Nadelmann E, McNeely J, Drucker E. International perspectives on harm reduction. In: Lowinson J, Ruiz P, Millman M, Langrod J. Substance abuse: a comprehensive textbook. 4th ed. New York: Wiley; 1997. 53. Shea C. Thou shalt not. Washingtonian 1998;10(15):71. {MAP URL: http://www.mapinc.org/drugnews/v98/n1082/a02.html } 54. McCaffery BR. Decriminalizing drugs is wrong. Cinncinnati Enquirer 1998 Aug 6. 55. Substance Abuse and Mental Health Services Administration (US). Historical estimates from the Drug Abuse Warning Network: 1978–1994 estimates of drug-related emergency department episodes. Advance Report No. 16. Rockville (MD): Department of Health and Human Services; 1996. end
|